Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

Biotech firms in Germany raised notably less money last year than in 2024, according to a report released by the consultancy ...

This Biotech Stock Is Up 85%. FDA Has Agreed to Review a Skin Cancer Drug. Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...

GSK’s latest hepatology partnership is posing a less-asked question—how do you stop patients’ liver fibrosis from regressing?

The structural advantages that allow China to conduct clinical trials more quickly and at lower costs should be leveraged to ...